Immatics N.V. (NASDAQ:IMTX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Immatics N.V. (NASDAQ:IMTX) have been given an average rating of “Moderate Buy” by the eight brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $20.80.

IMTX has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (d)” rating on shares of Immatics in a report on Tuesday. Chardan Capital restated a “buy” rating and set a $25.00 target price on shares of Immatics in a report on Tuesday, May 19th. TD Cowen initiated coverage on Immatics in a report on Tuesday, April 28th. They set a “buy” rating on the stock. Mizuho set a $25.00 target price on Immatics in a report on Thursday, February 19th. Finally, Wall Street Zen cut Immatics from a “hold” rating to a “sell” rating in a report on Saturday, May 2nd.

Immatics Stock Up 3.5%

Immatics stock opened at $9.38 on Friday. The business’s 50-day simple moving average is $10.78 and its 200 day simple moving average is $10.25. The stock has a market cap of $1.26 billion, a price-to-earnings ratio of -4.71 and a beta of 1.30. Immatics has a 12-month low of $5.05 and a 12-month high of $12.41.

Immatics (NASDAQ:IMTX) last issued its earnings results on Tuesday, May 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.08). Immatics had a negative return on equity of 47.36% and a negative net margin of 572.35%.The company had revenue of $8.81 million for the quarter, compared to the consensus estimate of $9.79 million. As a group, sell-side analysts expect that Immatics will post -1.67 EPS for the current year.

Hedge Funds Weigh In On Immatics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jefferies Financial Group Inc. raised its position in shares of Immatics by 323.4% during the fourth quarter. Jefferies Financial Group Inc. now owns 5,059,551 shares of the company’s stock worth $53,125,000 after purchasing an additional 3,864,636 shares during the period. RTW Investments LP raised its position in shares of Immatics by 29.7% during the fourth quarter. RTW Investments LP now owns 11,433,354 shares of the company’s stock worth $120,050,000 after purchasing an additional 2,617,737 shares during the period. T. Rowe Price Investment Management Inc. raised its position in shares of Immatics by 10.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 21,459,156 shares of the company’s stock worth $225,322,000 after purchasing an additional 2,075,987 shares during the period. Baker BROS. Advisors LP raised its position in shares of Immatics by 18.9% during the third quarter. Baker BROS. Advisors LP now owns 12,094,094 shares of the company’s stock worth $103,042,000 after purchasing an additional 1,925,193 shares during the period. Finally, Sofinnova Investments Inc. raised its position in shares of Immatics by 54.2% during the fourth quarter. Sofinnova Investments Inc. now owns 3,435,542 shares of the company’s stock worth $36,073,000 after purchasing an additional 1,207,705 shares during the period. Institutional investors own 64.41% of the company’s stock.

Immatics Company Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.